Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anebulo Pharmaceuticals, Inc. faces a significant business risk as it seeks stockholder approval for a reverse stock split, part of a plan to go private and delist from the Nasdaq Stock Market. This move could lead to reduced transparency and liquidity, as the company would no longer file regular reports with the SEC, making it harder for investors to access information. The potential delisting and deregistration may also decrease the stock’s value due to limited trading options, primarily through private sales or the OTC market, if available. The decision to proceed with the reverse stock split and subsequent actions rests with the board, which may abandon the plan if deemed not in the company’s best interests.
Overall, Wall Street has a Hold consensus rating on ANEB stock based on 1 Hold.
To learn more about Anebulo Pharmaceuticals, Inc.’s risk factors, click here.